Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.20
Bid: 8.10
Ask: 8.30
Change: 0.05 (0.61%)
Spread: 0.20 (2.469%)
Open: 8.20
High: 8.30
Low: 8.15
Prev. Close: 8.15
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Update: Liberation Labs

30 Dec 2022 12:00

RNS Number : 3571L
Agronomics Limited
30 December 2022
 

 

Agronomics Limited

 

("Agronomics" or the "Company")

 

Portfolio Company Liberation Labs Announces Final Close of Seed Financing

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture, is pleased to announce that Liberation Labs Holdings Inc ("Liberation Labs"), the large-scale precision fermentation contract manufacturer, has completed the final close of its Seed financing as most recently announced by the Company on 5 December 2022. Liberation Labs will use the proceeds to purchase and begin development of the site where it will build its first commercial-scale 600,000L launch facility.

The Company holds a total of 4,700,000 ordinary shares and 2,134,147 Seed Preferred shares, in Liberation Labs, with an equity ownership of 37.4% on a fully diluted basis. The aggregate investment will account for approximately 11.3% of the last published Net Asset Value of Agronomics (30.09.22) (as adjusted for the uplift on the Liberation Labs position).

The full announcement is set out below without any material changes.

 

Liberation Labs Announces Final Close of $20 Million in Seed Financing

Capital will be used to build out a 600,000 liter production facility in the U.S. to meet surging demand for novel proteins from both traditional and food-tech companies

 

NEW YORK (December 30, 2022) Liberation Labs, the developer of a precision fermentation platform for the production of alternative proteins at scale, has closed a $20 million seed round of funding. The round was led by Agronomics and Siddhi Capital and includes CPT Capital, Thia Ventures, 8090 Industries and Echo. Funds will be used for, among other things, the purchase and development of a site on which to build its first commercial-scale Launch Facility, which will have a fermentation capacity of 600,000 liters with a fully dedicated downstream process (DSP).

"Liberation Labs aims to dramatically increase availability of precision fermentation capacity to meet the rising demand for alternative proteins, fueled by population growth and increasingly health-conscious, impact-driven consumers," said Mark Warner, co-founder and CEO of Liberation Labs. "Our business model enables us to not only meet the demand from today's traditional food companies but unlock innovation among the dozens of emerging food-tech companies."

Liberation Labs is commercializing precision fermentation with a global network of purpose built, international manufacturing facilities that enable the next wave of biotechnology advancements to produce alternative protein at scale.

"Liberation Labs has the potential to dramatically accelerate adoption of novel proteins that are increasingly in demand by both existing and next-gen food companies responding to changing consumer preferences," said Jim Mellon, co-founder and executive director at Agronomics. "We believe they will set a new standard in the industry and usher in a new era of innovation in healthy, sustainable and scalable foods."

With the close of the seed round, the company's focus is turned completely to finalizing the site selection process and the completion of Front End Loading level 3 engineering (FEL-3), followed by placing orders for long-lead equipment and building out the operations team. Liberation Labs is projecting commissioning and commercial production of its first facility by the end of 2024.

 

"We're confident in the experience and talent of the senior executive team at Liberation Labs to deliver on a novel approach to precision fermentation," said Steven Finn, co-founder and co-managing partner of Siddhi Capital. "We believe they can make a significant contribution to making the global food system more sustainable and scaleable."

About Liberation Labs

Liberation Labs is commercializing precision fermentation with a global network of purpose built, international manufacturing facilities that enable the next wave of biotechnology advancements to produce alternative protein at scale. Our cutting-edge process combining modern technology and design brings reliable, fit-for-purpose approach and cost-effective solutions that meet consumer demand across the world.

 

Founded by industry pioneers with a combined 50 years of experience, Liberation Labs is powering a new, innovative way forward that sets the standard for the precision fermentation food industry to make a lasting impact on achieving food security for the world's growing population. More information is available at http://www.liberationlabs.com/

Media Contact

John Williams, Scoville PR for Liberation Labs

+1-206-660-5503, jwilliams@scovillepr.com

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

 

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord

Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

 

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen 

(Head of Equities)

Giles Balleny

Max Gould

Michael Johnson

Lucy Williams

Charles Goodfellow

 Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

 

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATMBMTMTAJBLT
Date   Source Headline
4th Dec 20197:00 amRNSUpdate on Placing and Final Results
11th Nov 20197:00 amRNSProposed Fundraise
29th Oct 20197:00 amRNSInvestment in Shiok Meats Pte. Ltd.
22nd Oct 20192:00 pmRNSCompany Newsletter
17th Oct 20197:00 amRNSInvestment in VitroLabs Inc
15th Oct 20197:00 amRNSInvestment in Rebellyous Foods
8th Oct 20197:00 amRNSNet Asset Value(s)
23rd Sep 20191:00 pmRNSAIM Rule 17 Notification
12th Sep 20197:00 amRNSInvestee Company Update
9th Sep 201911:55 amRNSHolding(s) in Company
5th Sep 20197:00 amRNSSeed Investment in Bond Pets LLC
29th Aug 20197:00 amRNSAgronomics Participates in BlueNalu Fund Raise
28th Aug 20199:42 amRNSNew website launched
27th Aug 20191:21 pmRNSInvestee company Update: Blue Nalu, Inc
12th Aug 201912:51 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNet Asset Value(s)
29th Jul 20197:00 amRNSInvestment in Simply Foods, Inc. (New Age Meats)
5th Jul 20194:40 pmRNSSecond Price Monitoring Extn
5th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 201912:58 pmRNSResult of Meeting
17th Jun 20192:05 pmRNSSecond Price Monitoring Extn
17th Jun 20192:00 pmRNSPrice Monitoring Extension
17th Jun 201911:00 amRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSEquity Fundraise Closes at £4.5 million
10th Jun 20197:00 amRNSProposed Equity Fundraise
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.